NMPA Approval

Fluticasone Propionate Inhalation Aerosol

Approval Number

H20130190

CompanyGlaxosmithkline Australia Pty Ltd.

Registration Date

December 27, 2019

Previous Approval Numbers

H20130190

Drug Information

Generic Name

丙酸氟替卡松吸入气雾剂

Trade Name

辅舒酮

Brand Name

辅舒酮

Dosage Form

吸入气雾剂

Strength

每瓶60揿，每揿含丙酸氟替卡松125μg，递送剂量为丙酸氟替卡松110μg；每瓶120揿，每揿含丙酸氟替卡松125μg，递送剂量为丙酸氟替卡松110μg

Drug Type

化学药品

Registration Date

December 27, 2019

Expiry Date

December 20, 2023

Company Information

Applicant Company

Company NameGlaxosmithkline Australia Pty Ltd.

Company Address

Level 4/436 Johnston Street ABBOTSFORD VIC 3067 AUSTRALIA

Manufacturing Company

Company NameGlaxo Wellcome SA

Company Address

Avda de Extremadura 3 Poligono Industrial Allenduero Aranda De Duero, Burgos, 09400 Spain

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Product

Company

Legal

© 2025 MedPath, Inc. All rights reserved.

丙酸氟替卡松吸入气雾剂 - NMPA 批准文号 | MedPath